<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Abbvie Inc — News on 6ix</title>
<link>https://6ix.com/company/abbvie-inc</link>
<description>Latest news and press releases for Abbvie Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 11:47:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/abbvie-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683540ac0eaa31f6af967762.webp</url>
<title>Abbvie Inc</title>
<link>https://6ix.com/company/abbvie-inc</link>
</image>
<item>
<title>AbbVie Reports First-Quarter 2026 Financial Results</title>
<link>https://6ix.com/company/abbvie-inc/news/abbvie-reports-first-quarter-2026-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/abbvie-reports-first-quarter-2026-financial-results</guid>
<pubDate>Wed, 29 Apr 2026 11:47:00 GMT</pubDate>
<description>AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2026.</description>
</item>
<item>
<title>AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata</title>
<link>https://6ix.com/company/abbvie-inc/news/abbvie-submits-application-to-fda-for-upadacitinib-rinvoqr-for-adults-and-adolescents-with-severe-alopecia-areata</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/abbvie-submits-application-to-fda-for-upadacitinib-rinvoqr-for-adults-and-adolescents-with-severe-alopecia-areata</guid>
<pubDate>Tue, 28 Apr 2026 12:00:00 GMT</pubDate>
<description>AbbVie (NYSE: ABBV) today announced that it has submitted an application for a new indication to the U.S. Food and Drug Administration (FDA) for upadacitinib (RINVOQ®; 15 mg and 30 mg, once daily) for the treatment of adult and adolescent patients with severe alopecia areata (AA), based on results from the Phase 3 UP-AA clinical program.1-3</description>
</item>
<item>
<title>RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF inhibitor</title>
<link>https://6ix.com/company/abbvie-inc/news/rinvoqr-upadacitinib-demonstrated-superiority-versus-humirar-adalimumab-for-primary-endpoint-in-a-head-to-head-study-in-rheumatoid-arthritis-patients-who-have-failed-first-tnf-inhibitor</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/rinvoqr-upadacitinib-demonstrated-superiority-versus-humirar-adalimumab-for-primary-endpoint-in-a-head-to-head-study-in-rheumatoid-arthritis-patients-who-have-failed-first-tnf-inhibitor</guid>
<pubDate>Tue, 28 Apr 2026 11:01:00 GMT</pubDate>
<description>Today, AbbVie (NYSE: ABBV) announced positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study evaluating the efficacy and safety of upadacitinib (RINVOQ®) 15 mg, once daily, compared to adalimumab (HUMIRA®) 40 mg, every other week, in adult patients with moderate to severe rheumatoid arthritis (RA) on a stable background of methotrexate (MTX) who had an inadequate response or intolerance to a TNF inhibitor (TNFi) other than adalimumab.1 This study achieved the primary endpoi</description>
</item>
<item>
<title>AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease</title>
<link>https://6ix.com/company/abbvie-inc/news/abbvie-submits-regulatory-application-to-fda-for-skyrizir-risankizumab-rzaa-subcutaneous-induction-for-adults-with-moderately-to-severely-active-crohns-disease</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/abbvie-submits-regulatory-application-to-fda-for-skyrizir-risankizumab-rzaa-subcutaneous-induction-for-adults-with-moderately-to-severely-active-crohns-disease</guid>
<pubDate>Mon, 27 Apr 2026 12:05:00 GMT</pubDate>
<description>AbbVie (NYSE: ABBV) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for SKYRIZI® (risankizumab-rzaa) for subcutaneous (SC) induction for the treatment of adult patients with moderately to severely active Crohn's disease (CD).</description>
</item>
<item>
<title>AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.</title>
<link>https://6ix.com/company/abbvie-inc/news/abbvie-provides-update-on-trenibotulinumtoxine-trenibote-biologics-license-application-in-the-us</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/abbvie-provides-update-on-trenibotulinumtoxine-trenibote-biologics-license-application-in-the-us</guid>
<pubDate>Thu, 23 Apr 2026 20:05:00 GMT</pubDate>
<description>AbbVie (NYSE: ABBV) today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for trenibotulinumtoxinE (TrenibotE), a first-in-class botulinum neurotoxin serotype E with a rapid onset of effect and short duration.</description>
</item>
<item>
<title>AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus</title>
<link>https://6ix.com/company/abbvie-inc/news/abbvie-selects-north-carolina-for-new-dollar14-billion-manufacturing-campus</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/abbvie-selects-north-carolina-for-new-dollar14-billion-manufacturing-campus</guid>
<pubDate>Wed, 22 Apr 2026 16:00:00 GMT</pubDate>
<description>AbbVie (NYSE: ABBV) today announced a $1.4 billion investment to build a 185-acre pharmaceutical manufacturing campus in Durham, North Carolina. The state-of-the-art campus will integrate advanced manufacturing and laboratory technologies with artificial intelligence (AI) to support the production of AbbVie's immunology, neuroscience and oncology medicines.</description>
</item>
<item>
<title>AbbVie and BioLabs Team Up to Support Life Sciences Innovation in Canada</title>
<link>https://6ix.com/company/abbvie-inc/news/abbvie-and-biolabs-team-up-to-support-life-sciences-innovation-in-canada</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/abbvie-and-biolabs-team-up-to-support-life-sciences-innovation-in-canada</guid>
<pubDate>Mon, 20 Apr 2026 19:00:00 GMT</pubDate>
<description>Today, AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, announced the expansion of its partnership with BioLabs by becoming the founding sponsor of the new BioLabs University of Toronto. The AbbVie and BioLabs collaboration will accelerate important life science research, with the goal of benefiting people living with serious diseases.</description>
</item>
<item>
<title>Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases</title>
<link>https://6ix.com/company/abbvie-inc/news/nxera-pharma-to-receive-usdollar10-million-milestone-payment-from-abbvie-under-collaboration-targeting-neurological-diseases-1</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/nxera-pharma-to-receive-usdollar10-million-milestone-payment-from-abbvie-under-collaboration-targeting-neurological-diseases-1</guid>
<pubDate>Mon, 20 Apr 2026 06:30:00 GMT</pubDate>
<description>This marks the third milestone achieved under the collaboration and reflects the steady progress of the pipelineUnder the terms of the agreement, Nxera is eligible to receive up to US$1.2 billion in potential option, development and commercial milestones, in addition to tiered royalties based on sales Tokyo, Japan and Cambridge and London, UK, 20 April 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a third R&D milestone under its multi-target dis</description>
</item>
<item>
<title>Middle East and Africa Biosimilars Market Trends Report 2026-2035, Profiles of AbbVie, Amgen, Biocon, Celltrion, Dr. Reddy's, Pfizer, Roche, Samsung, Sandoz, Teva, Viatris</title>
<link>https://6ix.com/company/abbvie-inc/news/middle-east-and-africa-biosimilars-market-trends-report-2026-2035-profiles-of-abbvie-amgen-biocon-celltrion-dr-reddys-pfizer-roche-samsung-sandoz-teva-viatris</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/middle-east-and-africa-biosimilars-market-trends-report-2026-2035-profiles-of-abbvie-amgen-biocon-celltrion-dr-reddys-pfizer-roche-samsung-sandoz-teva-viatris</guid>
<pubDate>Fri, 17 Apr 2026 10:17:00 GMT</pubDate>
<description>The Middle East and Africa biosimilars market is poised for strong growth due to patent expiries, increased chronic disease prevalence, and supportive regulations. High demand for affordable biologics, especially for oncological and chronic conditions, presents significant market opportunities amidst challenges like high development costs and regulatory complexities. Middle Eastern and African Biosimilars Market Middle Eastern and African Biosimilars Market Dublin, April 17, 2026 (GLOBE NEWSWIRE</description>
</item>
<item>
<title>Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain</title>
<link>https://6ix.com/company/abbvie-inc/news/haisco-enters-into-exclusive-license-agreement-with-abbvie-to-develop-novel-medicines-for-pain</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/haisco-enters-into-exclusive-license-agreement-with-abbvie-to-develop-novel-medicines-for-pain</guid>
<pubDate>Mon, 13 Apr 2026 06:24:00 GMT</pubDate>
<description>On April 10, 2026, Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with AbbVie (NYSE: ABBV), a global biopharmaceutical company. Under the agreement, Haisco grants AbbVie the exclusive rights to develop, manufacture, and commercialize novel medicines for the treatment of pain globally, excluding mainland China, Hong Kong, and Macau.</description>
</item>
<item>
<title>AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026</title>
<link>https://6ix.com/company/abbvie-inc/news/abbvie-showcases-latebreaking-phase-2-data-for-mirvetuximab-soravtansine-gynx-elaherer-in-platinumsensitive-ovarian-cancer-psoc-at-sgo-2026</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/abbvie-showcases-latebreaking-phase-2-data-for-mirvetuximab-soravtansine-gynx-elaherer-in-platinumsensitive-ovarian-cancer-psoc-at-sgo-2026</guid>
<pubDate>Sun, 12 Apr 2026 11:15:00 GMT</pubDate>
<description>AbbVie (NYSE: ABBV) today announced that late-breaking results from the Phase 2 IMGN853-0420 trial will be presented in an oral session at the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting (San Juan, Puerto Rico; April 10-13, 2026). The study evaluated the potential efficacy and safety of mirvetuximab soravtansine-gynx, a first-in-class antibody-drug conjugate (ADC), in combination with carboplatin followed by maintenance of mirvetuximab soravtansine-gynx monotherapy, in patients wit</description>
</item>
<item>
<title>BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year</title>
<link>https://6ix.com/company/abbvie-inc/news/botoxr-cosmetic-onabotulinumtoxina-empowers-women-entrepreneurs-through-the-confidence-collective-for-fourth-year</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/botoxr-cosmetic-onabotulinumtoxina-empowers-women-entrepreneurs-through-the-confidence-collective-for-fourth-year</guid>
<pubDate>Wed, 08 Apr 2026 12:00:00 GMT</pubDate>
<description>Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced that applications are now open for The Confidence Collective: Empowering Women Entrepreneurs, an ongoing initiative from BOTOX® Cosmetic dedicated to uplifting and investing in businessowners. Applications are open now through April 29, 2026.</description>
</item>
<item>
<title>Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin</title>
<link>https://6ix.com/company/abbvie-inc/news/allergan-aesthetics-third-state-of-the-art-ami-center-opens-in-austin</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/allergan-aesthetics-third-state-of-the-art-ami-center-opens-in-austin</guid>
<pubDate>Tue, 07 Apr 2026 13:00:00 GMT</pubDate>
<description>Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, today announced the opening of the new AMI Austin in Texas. This location marks the third U.S. AMI Training Center opened in the past year and reflects continued investment in aesthetics education.</description>
</item>
<item>
<title>Mission BioCapital Announces Opening of $4 Million 2026 Platinum Program Contest and 2025 Platinum Ticket Investments</title>
<link>https://6ix.com/company/abbvie-inc/news/mission-biocapital-announces-opening-of-dollar4-million-2026-platinum-program-contest-and-2025-platinum-ticket-investments</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/mission-biocapital-announces-opening-of-dollar4-million-2026-platinum-program-contest-and-2025-platinum-ticket-investments</guid>
<pubDate>Thu, 02 Apr 2026 12:00:00 GMT</pubDate>
<description>Mission BioCapital (MBC), in partnership with sponsors AbbVie, Ono Venture Investment (OVI), Toronto Innovation Acceleration Partners (TIAP), Connecticut Innovations, Alloy Therapeutics, HitGen, CCRM, Goodwin, Norton Rose Fulbright, and van den Boom & Associates announced today that applications are open internationally for the 2026 Platinum Program. MBC's Platinum Program aims to advance high-potential life sciences start-up companies by providing pre-seed funding, global laboratory space, expe</description>
</item>
<item>
<title>/C O R R E C T I O N -- AbbVie/</title>
<link>https://6ix.com/company/abbvie-inc/news/c-o-r-r-e-c-t-i-o-n-abbvie</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/c-o-r-r-e-c-t-i-o-n-abbvie</guid>
<pubDate>Tue, 31 Mar 2026 14:04:00 GMT</pubDate>
<description>Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced its fourth annual CoolMonth, featuring exclusive offers on CoolSculpting®, the treatment doctors use most for nonsurgical fat reduction.1</description>
</item>
<item>
<title>AbbVie to Host First-Quarter 2026 Earnings Conference Call</title>
<link>https://6ix.com/company/abbvie-inc/news/abbvie-to-host-first-quarter-2026-earnings-conference-call</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/abbvie-to-host-first-quarter-2026-earnings-conference-call</guid>
<pubDate>Tue, 31 Mar 2026 12:00:00 GMT</pubDate>
<description>AbbVie (NYSE: ABBV) will announce its first-quarter 2026 financial results on Wednesday, April 29, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.</description>
</item>
<item>
<title>Allergan Aesthetics Releases Findings on the Safety and Efficacy of Repeat TrenibotE Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors at the 2026 American Academy of Dermatology Meeting (AAD)</title>
<link>https://6ix.com/company/abbvie-inc/news/allergan-aesthetics-releases-findings-on-the-safety-and-efficacy-of-repeat-trenibote-treatments-and-data-on-medical-weight-loss-aesthetics-patient-behaviors-at-the-2026-american-academy-of-dermatology-meeting-aad</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/allergan-aesthetics-releases-findings-on-the-safety-and-efficacy-of-repeat-trenibote-treatments-and-data-on-medical-weight-loss-aesthetics-patient-behaviors-at-the-2026-american-academy-of-dermatology-meeting-aad</guid>
<pubDate>Mon, 30 Mar 2026 12:00:00 GMT</pubDate>
<description>Allergan Aesthetics, an AbbVie company, presented four posters at the American Academy of Dermatology Meeting (AAD), highlighting the safety and efficacy of new and emerging products in our aesthetics portfolio and insights on the aesthetic mindset of an emerging patient population.</description>
</item>
<item>
<title>AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting</title>
<link>https://6ix.com/company/abbvie-inc/news/abbvie-to-highlight-new-clinical-and-real-world-evidence-advancing-standards-of-care-in-immune-mediated-skin-diseases-at-the-2026-aad-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/abbvie-to-highlight-new-clinical-and-real-world-evidence-advancing-standards-of-care-in-immune-mediated-skin-diseases-at-the-2026-aad-annual-meeting</guid>
<pubDate>Fri, 27 Mar 2026 14:00:00 GMT</pubDate>
<description>AbbVie (NYSE: ABBV) today announced new research across its dermatology portfolio to be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, March 27–31 in Denver, Colorado.</description>
</item>
<item>
<title>Allergan Aesthetics Reinforces Scientific Differentiation and Leadership with 21 Evidence-Based E-Posters at the 2026 Aesthetic & Anti-Aging Medicine World Congress (AMWC)</title>
<link>https://6ix.com/company/abbvie-inc/news/allergan-aesthetics-reinforces-scientific-differentiation-and-leadership-with-21-evidence-based-e-posters-at-the-2026-aesthetic-and-anti-aging-medicine-world-congress-amwc</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/allergan-aesthetics-reinforces-scientific-differentiation-and-leadership-with-21-evidence-based-e-posters-at-the-2026-aesthetic-and-anti-aging-medicine-world-congress-amwc</guid>
<pubDate>Thu, 26 Mar 2026 08:00:00 GMT</pubDate>
<description>Allergan Aesthetics, an AbbVie company, will present 21 scientific e-posters at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) in Monaco on March 26-28, 2026, underscoring the company's industry leadership in advancing patient-centric, evidence-based innovation across the spectrum of aesthetics medicine. The data span clinical, real-world and preclinical research, reflecting a deep commitment to driving exceptional results, safety and satisfaction for practitioners and patients worldw</description>
</item>
<item>
<title>Allergan Aesthetics Ushers in a New Age of Hyaluronic Acid (HA) Injectables with JUVÉDERM® at AMWC Monaco</title>
<link>https://6ix.com/company/abbvie-inc/news/allergan-aesthetics-ushers-in-a-new-age-of-hyaluronic-acid-ha-injectables-with-juvedermr-at-amwc-monaco</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/allergan-aesthetics-ushers-in-a-new-age-of-hyaluronic-acid-ha-injectables-with-juvedermr-at-amwc-monaco</guid>
<pubDate>Thu, 26 Mar 2026 07:00:00 GMT</pubDate>
<description>Allergan Aesthetics, an AbbVie company, a global leader in medical aesthetics treatments and manufacturers of the market-leading JUVÉDERM® Collection of Fillers,3,4,‖ is once again forging ahead and has announced that the 'Undetectable† Era' will drive the next chapter in the Hyaluronic Acid (HA) injectable category at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) 2026 in Monaco.</description>
</item>
</channel>
</rss>